Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Timing appears essential to combining antiangiogenesis and radiation therapy

21.12.2004


MGH study provides clues to best therapeutic schedule, cellular underpinnings of treatment



Although the earliest clinical trials of the cancer-fighting potential of antiangiogenesis drugs did not have the dramatic results that some hoped for, subsequent trials showed that combining agents that suppress blood-vessel growth with therapies that destroy cancer cells can improve patient survival. In the December issue of Cancer Cell, researchers from the Massachusetts General Hospital (MGH) describe how timing may be crucial to successfully combining angiogenesis inhibitors with radiation treatment and reveal more about exactly how these drugs work to fight cancer, which is somewhat different from earlier theories.

"The blood vessels that develop to supply nutrients to a tumor are not normal," says Rakesh Jain, PhD, director of the Steele Laboratory in the MGH Department of Radiation Therapy, the study’s senior author. "The vessels are leaky, dilated, disfigured, and do not evenly inflitrate the tumor, which can interfere with standard cancer therapies. Chemotherapy drugs are not distributed throughout the tumor, and the oxygen level is low, making tumors resistant to radiation therapy. It now appears that antiangiogenic therapy transiently improves a tumor’s blood supply and oxygenation, making it more vulnerable to radiation therapy."


Although some animal studies have suggested that combining antiangiogenesis and radiation therapy can slow tumor growth, in others the treatment appeared to spur tumor growth. The current investigation was designed to resolve these conflicting results and to improve understanding of the cellular and molecular underpinnings of antiangiogenesis treatment. The MGH researchers implanted human brain tumor tissue into mice that were then treated with various combinations of an angiogenesis inhibitor called DC101 and radiation therapy.

DC101 alone produced a minor delay in tumor growth, and radiation alone produced a more significant growth delay. But of five different schedules of combined treatment, only giving radiation from 4 to 6 days after initiation of DC101 therapy resulted in a synergistic effect that was greater than simply adding the effects of both treatments. Measurement of the oxygen levels within tumor tissue supported the theory that DC101 improves oxygen delivery to the tumor during the same time period, with hypoxia (oxygen starvation) almost eliminated on day 5 but returning by day 8.

To better understand the mechanism behind these changes, the researchers conducted several detailed analyses of the tumor tissue. They observed a shift toward more normal blood vessels that were smaller and less disfigured after DC101 treatment and also found that these vessels had been stabilized by the recruitment of pericytes – cells that normally help to support blood vessel walls. Mirroring the pattern of oxygen supply, pericyte coverage of blood vessels peaked around day 5 and then fell off by day 8.

The investigators also showed that greater pericyte coverage was the result of more pericytes being attracted to the tumor vessels, rather than the removal of pericyte-poor vessels as some researchers had assumed. Measurement of a factor known to be involved in pericyte recruitment found that its levels were temporarily increased after DC101 treatment. Examination of the effects of DC101 on vascular cells’ basement membrane, which becomes abnormally thick in tumors, indicated that the membrane was thinner during the day-2-to-day-5 time period and also showed that this improvement resulted from the increased activity of specific enzymes.

One crucial result of these findings is alleviation of the concern that reducing a tumor’s blood supply would actually worsen hypoxia and increase resistance to radiation therapy. "The success of this treatment approach depends on carefully scheduling when radiation is administered to take the greatest advantage of this window of vascular normalization," says Jain, who is Cook Professor of Tumor Biology at Harvard Medical School. His group plans further studies to determine how these results could be applied to treatment of cancer patients.

Additional authors of the current study are co-first authors Frank Winkler, MD, PhD, and Sergey Kozin, PhD, along with Ricky Tong, Sung-Suk Chae, PhD, Michael Booth, PhD, Igor Garkavtsev, MD, PhD, Lei Xu, MD, PhD, Dai Fukumura, MD, PhD, Emmanuelle di Tomaso, PhD, and Lance Munn, PhD, all of the Steele Laboratory at MGH; and Daniel Hicklin, PhD, of ImClone Systems Incorporated in New York.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.

The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Quantum bugs, meet your new swatter

20.08.2018 | Information Technology

A novel synthetic antibody enables conditional “protein knockdown” in vertebrates

20.08.2018 | Life Sciences

Metamolds: Molding a mold

20.08.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>